Positive results from phase III CodeBreaK 300 study evaluating Lumakras + Vectibix vs current standard of care in chemo-refractory metastatic KRAS G12C mutated colorectal cancer.- Amgen
The global Phase III CodeBreaK 300 study evaluating Lumakras combined with Vectibix vs current standard of care in chemo-refractory metastatic KRAS G12C mutated colorectal cancer (CRC) met its primary endpoint of progression-free survival (PFS) for both the 240 mg and 960 mg doses of Lumakras. At comparable doses, efficacy results were consistent with what was observed in CodeBreaK 101 with no new safety signals.
The Company will discuss these data with regulatory agencies to evaluate Lumakras in combination with Vectibix as a potential treatment for patients with metastatic KRAS G12C mutated CRC. Detailed results will be presented at an upcoming medical congress.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.